Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $315

Benzinga · 1d ago
Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $300 to $315.